-
Innovation Ranking
NewInnovation Ranking – Leap Therapeutics Inc
Leap Therapeutics Inc (Leap Therapeutics) is a clinical-stage biopharmaceutical company that develops novel therapeutics to treat patients with different types of cancer. The company’s pipeline products include DKN-01. DKN-1 is a monoclonal antibody that targets the Dickkopf-1 (DKK-1) protein, intended for the treatment of gastroesophageal cancer, prostate cancer and gynecologic cancer. FL-301, a monoclonal antibody that targets Claudin18.2, is being tested in patients with gastric and pancreatic cancer. The company has an agreement with BeiGene Ltd for development rights and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sirexatamab in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sirexatamab in Epithelial Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sirexatamab in Epithelial Ovarian Cancer Drug Details: Sirexatamab (DKN-01, LY-2812176) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sirexatamab in Metastatic Biliary Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sirexatamab in Metastatic Biliary Tract Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sirexatamab in Metastatic Biliary Tract Cancer Drug Details: Sirexatamab (DKN-01,...
-
Product Insights
NewNet Present Value Model: Leap Therapeutics Inc’s Sirexatamab
Empower your strategies with our Net Present Value Model: Leap Therapeutics Inc's Sirexatamab report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sirexatamab in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sirexatamab in Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sirexatamab in Colorectal Cancer Drug Details: Sirexatamab (DKN-01, LY-2812176) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sirexatamab in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sirexatamab in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sirexatamab in Gastric Cancer Drug Details: Sirexatamab (DKN-01, LY-2812176) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sirexatamab in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sirexatamab in Hepatocellular Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sirexatamab in Hepatocellular Carcinoma Drug Details: Sirexatamab (DKN-01, LY-2812176) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sirexatamab in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sirexatamab in Endometrial Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sirexatamab in Endometrial Cancer Drug Details: Sirexatamab (DKN-01, LY-2812176) is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Sirexatamab in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sirexatamab in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sirexatamab in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: Sirexatamab (DKN-01,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Sirexatamab in Gallbladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sirexatamab in Gallbladder Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sirexatamab in Gallbladder Cancer Drug Details: Sirexatamab (DKN-01, LY-2812176) is under development...